Program
ZL-82
A development code. Also written as “The high-dose group of ZL-82 tablets”, “The low-dose group of ZL-82 tablets” and “ZL-82 12.5mg”.
Its studies are mostly in Dermatitis, Atopic · Arthritis, Rheumatoid, led by Chengdu Zenitar Biomedical Technology.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chengdu Zenitar Biomedical Technology | 31 open or running | phase 2since Apr 27, 2025 | Sep 19, 2023 | Dec 30, 2027phase 2 · NCT07193589 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 19, 2023First study: phase 1 study in Arthritis, RheumatoidFirst studyNCT06055023 · 69 enrolled · China
- Mar 24, 2024Phase 1 study in Healthy PersonNCT06432738 · 41 enrolled · China
- Apr 27, 2025Phase 2 study in Dermatitis, AtopicNCT07193589 · 111 planned · China
Ahead
- Dec 30, 2027Primary completion: phase 2 study in Dermatitis, AtopicNCT07193589
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07193589Dermatitis, Atopic · China | 2 | Recruiting | Dec 30, 2027 | 111 |
| NCT06432738Healthy Person · China | 1 | Completed | Aug 15, 2024 | 41 |
| NCT06055023Arthritis, Rheumatoid · China | 1 | Completed | Jan 28, 2024 | 69 |
How it is read
Names in the registry
- “The high-dose group of ZL-82 tablets”, 1 entry
- “The low-dose group of ZL-82 tablets”, 1 entry
- “ZL-82”, 1 entry
- “ZL-82 12.5mg”, 1 entry
- “ZL-82 25mg”, 1 entry
Codes read as this program: ZL82.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 1 study
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.